Scientific advances and increased awareness of the effect of testosterone deficiency (hypogonadism) on both sexual and general health reinforce the importance of managing testosterone deficiency (hypogonadism) effectively for the benefit of patients.

BSSM guidelines on adult testosterone deficiency, with statements for UK practice1

These statements have been developed for UK practice and aim to address the widespread media and scientific concerns over the appropriate treatment of men with testosterone deficiency with testosterone therapy. Written by the BSSM (British Society for Sexual Medicine) panel.

Read more Download

A practical guide from the BSSM on the assessment and management of testosterone deficiency in adult men1

This guide aims to provide a quick reference for UK healthcare professionals to recognise the issue and to manage the patients proactively and appropriately, based on the 2017 BSSM guidelines on adult testosterone deficiency, with statements for UK practice. Provided by the BSSM (British Society for Sexual Medicine)

Read more Download

Several international medical societies have issued recommendations on the diagnosis, treatment and monitoring of men with hypogonadism. We have included links to these guidelines along with a summary of the main points for the clinician to consider on the clinical guidelines for treatment of hypogonadism with testosterone therapy page.

Recommendation on the diagnosis, treatment and monitoring of hypogonadism in men

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud.

Read more Download
EAU Guidelines on Male Hypogonadism

Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging.

Read more Download

Clinical guidelines for treatment of hypogonadism with testosterone therapy

Read more

References

  • Hackett G, Kirby M, Wylie K, Heald A, Ossei-Gerning N, Edwards D, Muneer A. J Sex Med. 2018 Apr; 15(4):430-457. Return to content

Nebido® (testosterone undecanoate) is contraindicated in men with androgen-dependent carcinoma of the prostate. Careful an regular monitoring of the prostate gland must be performed in accordance with recommended methods (digital rectal examination and serum PSA measurement) in patients receiving testosterone therapy, especially in elderly and at risk patients. Local guidelines for safety monitoring should be taken into consideration. Please refer to the Summary of Product Characteristics for full details http://www.bayer.co.uk/en/businesses/bayer-healthcare/bayer-healthcare-pharma/our-products.

Alt tag
Clinical
updates

Keep up-to-date with the guidelines on men's health.

Alt tag
Educational
programme

CPD accredited online module to help you manage your male patients’ health.

Alt tag
Clinical
tools

Useful testosterone tools for the evaluation and management of your male patients.

Alt tag
Register for
latest news

Join 2,000 healthcare professionals and don’t miss out on the latest news.